Thursday, October 3, 2013
Biogen Idec Inc. and Evotec AG are taking opposite
strategies to finding new therapies for amyotrophic lateral sclerosis, a
disease with an unknown mechanism. Whereas Biogen Idec is forming partnerships
with multiple academic labs to solve the biology of the disease, Evotec is partnering
with the Harvard Stem Cell Institute at Harvard University to employ
phenotypic screens that circumvent the need to understand the mechanism from
Fishburn, C.S. SciBX 6(38); doi:10.1038/scibx.2013.1050
Published online Oct. 3, 2013
1. Chen, S. et al. Mol.
Neurodegen. 8, 28 (2013)
2. Fulmer, T. SciBX
3. Guruharsha, K.G. et
al. Cell 147, 690-703 (2011)
AND INSTITUTIONS MENTIONED
Biogen Idec Inc. (NASDAQ:BIIB), Weston, Mass.
Columbia University, New York, N.Y.
Duke University, Durham, N.C.
(Xetra:EVT), Hamburg, Germany
Harvard Medical School, Boston, Mass.
Harvard Stem Cell Institute, Cambridge, Mass.
Harvard University, Cambridge, Mass.
HudsonAlpha Institute for Biotechnology, Huntsville, Ala.
Isis Pharmaceuticals Inc. (NASDAQ:ISIS),
Knopp Biosciences LLC, Pittsburgh, Pa.
The Rockefeller University, New York, N.Y.
(Euronext:SAN; NYSE:SNY), Paris, France
Yale School of Medicine, New Haven, Conn.